This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

This move has been supported by a wide range of stocks, including AbbVie. Data by YCharts Investors have been buying AbbVie with both hands, as the company has proven it can move beyond the Humira ...

September 2024 A button-up shirt may be your closet’s stealthiest chameleon, equally at home in a blue-chip law firm, an oonz-oonz dance club, and a Sunday farmers market. But this undeniable ...

AbbVie shares are nearing $200, likely facing resistance and a potential pullback to test support between $175 and $185. Despite strong dividends and share buybacks, AbbVie’s higher P/E ratio ...

Every product on this page was chosen by a Harper's BAZAAR editor. We may earn commission on some of the items you choose to buy. While choosing a silhouette ultimately comes down to personal ...

One of the world's top biopharma companies, AbbVie (NYSE: ABBV) is a fairly complicated stock to approach as an independent investor. Aside from the scientific chops needed to evaluate the quality ...

But the risk of a serious side effect appears to be higher than previously known. By Anna Kodé AbbVie for years delayed competition for its blockbuster drug Humira, at the expense of patients and ...

AbbVie's Qulipta gains ground with docs for migraine prevention, as pharma looks to pressure Biohaven's Nurtec The top-selling CGRP is Pfizer’s Nurtec, which rang up sales of $928 million last year.

AbbVie did not immediately respond to a request for comment, but has previously said it expects to retain a lower share of the Humira market next year. Pharmacy benefit managers, which act as ...

AbbVie is a superbly managed organization. The company's leaders expertly positioned it for Humira's loss of patent protection. However, the shares look pricey at the moment. AbbVie is known as ...

Given its better valuation, we believe that Pfizer stock (NYSE: PFE) is currently a better pick than its industry peer – AbbVie stock . PFE stock trades at a much lower multiple of 11x forward ...

AbbVie's dividend growth has slowed, but new drugs are offsetting Humira's decline. The company's debt levels and payout ratio are high, but its shares screen as undervalued. Recent strategic ...